Inflammatory myofibroblastic tumor: A demographic, clinical and therapeutic study of 92 cases

Guoxiang Fu; Chuchu Xu; Nianfang Yao; Jianzhong Gu; Hanliang Jiang; Xufeng Han; Guoxiang Fu; Chuchu Xu; Nianfang Yao; Jianzhong Gu; Hanliang Jiang; Xufeng Han

doi:10.3934/mbe.2019339

Mathematical Biosciences and Engineering

2019, Volume 16, Issue 6: 6794-6804. doi: 10.3934/mbe.2019339

Previous Article Next Article

Research article Special Issues

Inflammatory myofibroblastic tumor: A demographic, clinical and therapeutic study of 92 cases

1.
Department of Pathology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
2.
Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
3.
Department of Respiration, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
4.
Department of Oncology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
5.
Department of Internal Medicine, Yuyao Traditional Chinese Medicine Hospital, Yuyao, Zhejiang, China

Received: 20 February 2019 Accepted: 10 July 2019 Published: 26 July 2019

Purpose: Inflammatory myofibroblastic tumors (IMT) was a rare kind of tumor defined by WHO since 2012. Little was known about this disease. There were controversies about IMT's behavior, predilection site, age distribution, and the best treatment methods. Here we provided a systematic overview on tumor demographical, clinical, biological features as well as treatment efficacy based on real cases from Surveillance, Epidemiology, and End Results (SEER) database. Methods: 92 patients diagnosed with IMT by histopathology were drawn from SEER database between 2002 and 2014. Patient demographics, clinical features and treatment information were analyzed. Results: The mean age of onset was 47.4 ± 22.4 years (0 to 83y) and the ages prone to this disease are middle-aged (from 41y to 64y), accounting for 1/3 of all patients. Three peak ages of onsets were 0–4y, 36–40y and more than 50y. 42% of the tumors were located in the soft tissues of limbs, hip, shoulder, head, face and neck. The average tumor sizes were 6.5 ± 5.3cm (1cm to 25cm). Survival in the group of tumor size smaller than 6.5cm was better compared to group of tumor size larger than 6.5cm (P < 0.05). Most of the tumors were malignant or malignant potential (89%), though local and distant metastasis rate were low (5%). Surgery was the most common treatment. However, the survival benefit was still uncertain compared to adjuvant chemotherapy or radiotherapy. Multivariate regression analysis demonstrated that young patients had better survival than old ones. Conclusions: IMT was a malignant tumor with low risk of local and distant metastasis. The peak ages were 0-4y, 36-40y and more than 50y. The prone sites were the soft tissues of the limbs, hip, shoulder, head, face and neck. Tumor sizes and ages were the factors correlated with survival time.
- Inflammatory myofibroblastic tumors,
- SEER database,
- clinical features,
- survival
Citation: Guoxiang Fu, Chuchu Xu, Nianfang Yao, Jianzhong Gu, Hanliang Jiang, Xufeng Han. Inflammatory myofibroblastic tumor: A demographic, clinical and therapeutic study of 92 cases[J]. Mathematical Biosciences and Engineering, 2019, 16(6): 6794-6804. doi: 10.3934/mbe.2019339

Related Papers:

Abstract

Purpose: Inflammatory myofibroblastic tumors (IMT) was a rare kind of tumor defined by WHO since 2012. Little was known about this disease. There were controversies about IMT's behavior, predilection site, age distribution, and the best treatment methods. Here we provided a systematic overview on tumor demographical, clinical, biological features as well as treatment efficacy based on real cases from Surveillance, Epidemiology, and End Results (SEER) database. Methods: 92 patients diagnosed with IMT by histopathology were drawn from SEER database between 2002 and 2014. Patient demographics, clinical features and treatment information were analyzed. Results: The mean age of onset was 47.4 ± 22.4 years (0 to 83y) and the ages prone to this disease are middle-aged (from 41y to 64y), accounting for 1/3 of all patients. Three peak ages of onsets were 0–4y, 36–40y and more than 50y. 42% of the tumors were located in the soft tissues of limbs, hip, shoulder, head, face and neck. The average tumor sizes were 6.5 ± 5.3cm (1cm to 25cm). Survival in the group of tumor size smaller than 6.5cm was better compared to group of tumor size larger than 6.5cm (P < 0.05). Most of the tumors were malignant or malignant potential (89%), though local and distant metastasis rate were low (5%). Surgery was the most common treatment. However, the survival benefit was still uncertain compared to adjuvant chemotherapy or radiotherapy. Multivariate regression analysis demonstrated that young patients had better survival than old ones. Conclusions: IMT was a malignant tumor with low risk of local and distant metastasis. The peak ages were 0-4y, 36-40y and more than 50y. The prone sites were the soft tissues of the limbs, hip, shoulder, head, face and neck. Tumor sizes and ages were the factors correlated with survival time.

References

[1]	B. C. Gleason and J. L. Hornick, Inflammatory myofibroblastic tumours: Where are we now?, J. Clin. Pathol., 61 (2008), 428–437.
[2]	A. M. Buccoliero, M. Ghionzoli, F. Castiglione, et al., Inflammatory myofibroblastic tumor: Clinical, morphological, immunohistochemical and molecular features of a pediatric case, Pathol. Res. Pract., 210 (2014), 1152–1155.
[3]	C. D. M. Fletcher, K. K. Unni and F. Mertens, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, J. Bone Joint Surg., (2002).
[4]	I. Karnak, M. E. Senocak, A. O. Ciftci, et al., Inflammatory myofibroblastic tumor in children: Diagnosis and treatment, J. Pediatr. Surg., 36 (2001), 908–912.
[5]	Y. S. Chun, L. Wang, A. G. Nascimento, et al., Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis, Pediatr. Blood Cancer, 45 (2005), 796–801.
[6]	C. M. Coffin, J. L. Hornick and C. D. Fletcher, Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases, Am. J. Surg. Pathol., 31 (2007), 509–520.
[7]	S. J. Kovach, A. C. Fischer, P. J. Katzman, et al., Inflammatory myofibroblastic tumors, J. Surg. Oncol., 94 (2006), 385–391.
[8]	M. Hausler, L. Schaade, V. T. Ramaekers, et al., Inflammatory pseudotumors of the central nervous system: Report of 3 cases and a literature review, Hum. Pathol., 34 (2003), 253–262.
[9]	A. Tomazic, D. Gvardijancic, J. Maucec, et al., Inflammatory myofibroblastic tumor of the pancreatic head - a case report of a 6 months old child and review of the literature, Radiol. Oncol., 49 (2015), 265–270.
[10]	J. T. Rabban, C. J. Zaloudek, K. M. Shekitka, et al., Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors, Am. J. Surg. Pathol., 29 (2005), 1348–1355.
[11]	M. H. Cessna, H. Zhou, W. G. Sanger, et al., Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases, Mod. Pathol., 15 (2002), 931–938.
[12]	C. M. Coffin, P. A. Humphrey and L. P. Dehner, Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey, Semin. Diagn. Pathol., 15 (1998), 85–101.
[13]	J. S. Janik, J. P. Janik, M. A. Lovell, et al., Recurrent inflammatory pseudotumors in children, J. Pediatr. Surg., 38 (2003), 1491–1495.
[14]	R. A. Morotti, M. D. Legman, N. Kerkar, et al., Pediatric inflammatory myofibroblastic tumor with late metastasis to the lung: case report and review of the literature, Pediatr. Dev. Pathol., 8 (2005), 224–229.
[15]	K. Schutte, A. Kandulski, D. Kuester, et al., Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature, Case. Rep. Gastroenterol., 4 (2010), 443–451.
[16]	M. K. Dishop, B. W. Warner, L. P. Dehner, et al., Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy, J. Pediatr. Hematol. Oncol., 25 (2003), 153–158.

Reader Comments

Your name:*

Email:*
© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)